Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

756 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L. Tsujino T, et al. Among authors: tsutsumi t. Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y. Nat Commun. 2023. PMID: 36650183 Free PMC article.
Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents.
Komura K, Inamoto T, Tsujino T, Matsui Y, Konuma T, Nishimura K, Uchimoto T, Tsutsumi T, Matsunaga T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirata K, Hirano H, Nomi H, Hirose Y, Ono F, Azuma H. Komura K, et al. Among authors: tsutsumi t. Oncogene. 2021 Oct;40(43):6210-6222. doi: 10.1038/s41388-021-02021-y. Epub 2021 Sep 20. Oncogene. 2021. PMID: 34545188 Free PMC article.
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.
Uchimoto T, Komura K, Fujiwara Y, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Uchimoto T, et al. Among authors: tsutsumi t. Med Oncol. 2019 Nov 21;37(1):9. doi: 10.1007/s12032-019-1332-7. Med Oncol. 2019. PMID: 31754918
Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in Japan.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: tsutsumi t. BJU Int. 2021 Feb;127(2):212-221. doi: 10.1111/bju.15187. Epub 2020 Aug 10. BJU Int. 2021. PMID: 32701219
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort.
Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Komura K, et al. Among authors: tsutsumi t. J Clin Med. 2019 Aug 19;8(8):1251. doi: 10.3390/jcm8081251. J Clin Med. 2019. PMID: 31430900 Free PMC article.
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: tsutsumi t. Cancers (Basel). 2021 Jan 30;13(3):526. doi: 10.3390/cancers13030526. Cancers (Basel). 2021. PMID: 33573172 Free PMC article.
The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma.
Tsujino T, Komura K, Ichihashi A, Tsutsumi T, Matsunaga T, Yoshikawa Y, Maenosono R, Okita K, Takai T, Oide R, Minami K, Uehara H, Taniguchi K, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Tsujino T, et al. Among authors: tsutsumi t. Oncotarget. 2017 Nov 25;8(66):110311-110325. doi: 10.18632/oncotarget.22688. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299149 Free PMC article.
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan.
Komura K, Hashimoto T, Tsujino T, Muraoka R, Tsutsumi T, Satake N, Matsunaga T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Uehara H, Tanaka T, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H. Komura K, et al. Among authors: tsutsumi t. Ann Surg Oncol. 2019 Sep;26(9):2994-3004. doi: 10.1245/s10434-019-07530-5. Epub 2019 Jun 25. Ann Surg Oncol. 2019. PMID: 31240592
Successful Treatment of Antibody-Mediated Rejection by De Novo Donor Specific Antibody After Primary Renal Transplantation in a Recipient From a Cadaveric Donor: A Case Report.
Matsunaga T, Hirano H, Maenosono R, Tsutsumi T, Tsujino T, Yoshikawa Y, Takai T, Minami K, Uehara H, Komura K, Nomi H, Ibuki N, Inamoto T, Azuma H. Matsunaga T, et al. Among authors: tsutsumi t. Transplant Proc. 2020 Jul-Aug;52(6):1928-1930. doi: 10.1016/j.transproceed.2020.01.150. Epub 2020 May 19. Transplant Proc. 2020. PMID: 32444119 Free article.
756 results